EUROPE IMMUNOGLOBULIN MARKET 2022-2028

 

TABLE OF CONTENTS

1.     EUROPE IMMUNOGLOBULIN MARKET – SUMMARY

2.     INDUSTRY OUTLOOK

2.1. IMPACT OF COVID-19 ON THE IMMUNOGLOBULIN MARKET

2.2. KEY INSIGHTS

2.2.1.    DEVELOPMENT OF NEW PURIFICATION METHODS

2.2.2.    INCREASING PREFERENCE FOR PERSONALIZED MEDICINES

2.3. PORTER’S FIVE FORCES ANALYSIS

2.3.1.    THREAT OF NEW ENTRANTS

2.3.2.    THREAT OF SUBSTITUTES

2.3.3.    BARGAINING POWER OF BUYERS

2.3.4.    BARGAINING POWER OF SUPPLIERS

2.3.5.    THREAT OF COMPETITIVE RIVALRY

2.4. MARKET ATTRACTIVENESS INDEX

2.5. VENDOR SCORECARD

2.6. KEY MARKET STRATEGIES

2.6.1.    PRODUCT LAUNCHES & DEVELOPMENTS

2.6.2.    PARTNERSHIPS & AGREEMENTS

2.7. MARKET DRIVERS

2.7.1.    GROWTH IN THE GERIATRIC POPULATION

2.7.2.    PREVALENCE OF IMMUNODEFICIENCY DISEASES AND AUTOIMMUNE DISORDERS

2.7.3.    INCREASING RESEARCH AND DEVELOPMENT ACTIVITIES

2.8. MARKET CHALLENGES

2.8.1.    HIGH COST OF THERAPY

2.8.2.    HIGH RISK OF SIDE EFFECTS DUE TO THE USE OF IMMUNOGLOBULIN

2.9. MARKET OPPORTUNITIES

2.9.1.    INCREASING ADOPTION OF INTRAVENOUS IMMUNOGLOBULIN (IVIG) TREATMENTS

2.9.2.    GROWING CLINICAL TRIALS

3.     EUROPE IMMUNOGLOBULIN MARKET OUTLOOK - BY TYPE

3.1. IGG

3.2. IGA

3.3. IGM

3.4. IGE

3.5. IGD

4.     EUROPE IMMUNOGLOBULIN MARKET OUTLOOK – BY DELIVERY MODE

4.1. INTRAVENOUS

4.2. SUBCUTANEOUS

4.3. INTRAMUSCULAR

5.     EUROPE IMMUNOGLOBULIN MARKET OUTLOOK – BY APPLICATION

5.1. HYPOGAMMA GLOBULINEMIA

5.2. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY

5.3. PRIMARY IMMUNODEFICIENCY DISEASES

5.4. MYASTHENIA GRAVIS

5.5. MULTIFOCAL MOTOR NEUROPATHY

5.6. IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)

5.7. INFLAMMATORY MYOPATHIES

5.8. SPECIFIC ANTIBODY DEFICIENCY

5.9. GUILLAIN-BARRE SYNDROME

5.10.               OTHER APPLICATIONS

6.     EUROPE IMMUNOGLOBULIN MARKET OUTLOOK – BY END-USER

6.1. HOSPITALS & CLINICS

6.2. HOMECARE

7.     EUROPE IMMUNOGLOBULIN MARKET OUTLOOK – BY SALES CHANNEL

7.1. HOSPITAL PHARMACY

7.2. SPECIALTY PHARMACY

7.3. OTHER SALES CHANNELS

8.     EUROPE IMMUNOGLOBULIN MARKET – COUNTRY OUTLOOK

8.1. UNITED KINGDOM

8.2. GERMANY

8.3. FRANCE

8.4. SPAIN

8.5. ITALY

8.6. REST OF EUROPE

9.     COMPETITIVE LANDSCAPE

9.1. BIOTEST AG

9.2. CHINA BIOLOGIC PRODUCTS INC

9.3. GRIFOLS SA

9.4. LFB GROUP

9.5. CSL BEHRING

9.6. KEDRION BIOPHARMA

9.7. OCTAPHARMA AG

9.8. TAKEDA PHARMACEUTICAL COMPANY LIMITED

9.9. BIO PRODUCTS LABORATORY

9.10.               SHANGHAI RAAS BLOOD PRODUCTS CO LTD

9.11.               PFIZER INC

9.12.               SANQUIN PLASMA PRODUCTS BV

9.13.               ADMA BIOLOGICS

9.14.               SICHUAN YUANDA SHUYANG PHARMACEUTICAL CO LTD

9.15.               KAMADA LTD

10. RESEARCH METHODOLOGY & SCOPE

10.1.               RESEARCH SCOPE & DELIVERABLES

10.2.               SOURCES OF DATA

10.3.               RESEARCH METHODOLOGY

 

TABLE LIST

TABLE 1: EUROPE IMMUNOGLOBULIN MARKET, BY COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)

TABLE 2: VENDOR SCORECARD

TABLE 3: EUROPE IMMUNOGLOBULIN MARKET, BY TYPE, 2022-2028 (IN $ MILLION)

TABLE 4: EUROPE IMMUNOGLOBULIN MARKET, BY DELIVERY MODE, 2022-2028 (IN $ MILLION)

TABLE 5: EUROPE IMMUNOGLOBULIN MARKET, BY APPLICATION, 2022-2028 (IN $ MILLION)

TABLE 6: EUROPE IMMUNOGLOBULIN MARKET, BY END-USER, 2022-2028 (IN $ MILLION)

TABLE 7: EUROPE IMMUNOGLOBULIN MARKET, BY SALES CHANNEL, 2022-2028 (IN $ MILLION)

TABLE 8: EUROPE IMMUNOGLOBULIN MARKET, BY COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)

 

FIGURE LIST

FIGURE 1: MARKET ATTRACTIVENESS INDEX

FIGURE 2: EUROPE IMMUNOGLOBULIN MARKET, BY TYPE, 2021 & 2028 (IN %)

FIGURE 3: EUROPE IMMUNOGLOBULIN MARKET, BY IGG, 2022-2028 (IN $ MILLION)

FIGURE 4: EUROPE IMMUNOGLOBULIN MARKET, BY IGA, 2022-2028 (IN $ MILLION)

FIGURE 5: EUROPE IMMUNOGLOBULIN MARKET, BY IGM, 2022-2028 (IN $ MILLION)

FIGURE 6: EUROPE IMMUNOGLOBULIN MARKET, BY IGE, 2022-2028 (IN $ MILLION)

FIGURE 7: EUROPE IMMUNOGLOBULIN MARKET, BY IGD, 2022-2028 (IN $ MILLION)

FIGURE 8: EUROPE IMMUNOGLOBULIN MARKET, BY DELIVERY MODE, 2021 & 2028 (IN %)

FIGURE 9: EUROPE IMMUNOGLOBULIN MARKET, BY INTRAVENOUS, 2022-2028 (IN $ MILLION)

FIGURE 10: EUROPE IMMUNOGLOBULIN MARKET, BY SUBCUTANEOUS, 2022-2028 (IN $ MILLION)

FIGURE 11: EUROPE IMMUNOGLOBULIN MARKET, BY INTRAMUSCULAR, 2022-2028 (IN $ MILLION)

FIGURE 12: EUROPE IMMUNOGLOBULIN MARKET, BY APPLICATION, 2021 & 2028 (IN %)

FIGURE 13: EUROPE IMMUNOGLOBULIN MARKET, BY HYPOGAMMA GLOBULINEMIA, 2022-2028 (IN $ MILLION)

FIGURE 14: EUROPE IMMUNOGLOBULIN MARKET, BY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY, 2022-2028 (IN $ MILLION)

FIGURE 15: EUROPE IMMUNOGLOBULIN MARKET, BY PRIMARY IMMUNODEFICIENCY DISEASES, 2022-2028 (IN $ MILLION)

FIGURE 16: EUROPE IMMUNOGLOBULIN MARKET, BY MYASTHENIA GRAVIS, 2022-2028 (IN $ MILLION)

FIGURE 17: EUROPE IMMUNOGLOBULIN MARKET, BY MULTIFOCAL MOTOR NEUROPATHY, 2022-2028 (IN $ MILLION)

FIGURE 18: EUROPE IMMUNOGLOBULIN MARKET, BY IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP), 2022-2028 (IN $ MILLION)

FIGURE 19: EUROPE IMMUNOGLOBULIN MARKET, BY INFLAMMATORY MYOPATHIES, 2022-2028 (IN $ MILLION)

FIGURE 20: EUROPE IMMUNOGLOBULIN MARKET, BY SPECIFIC ANTIBODY DEFICIENCY, 2022-2028 (IN $ MILLION)

FIGURE 21: EUROPE IMMUNOGLOBULIN MARKET, BY GUILLAIN-BARRE SYNDROME, 2022-2028 (IN $ MILLION)

FIGURE 22: EUROPE IMMUNOGLOBULIN MARKET, BY OTHER APPLICATIONS, 2022-2028 (IN $ MILLION)

FIGURE 23: EUROPE IMMUNOGLOBULIN MARKET, BY END-USER, 2021 & 2028 (IN %)

FIGURE 24: EUROPE IMMUNOGLOBULIN MARKET, BY HOSPITALS & CLINICS, 2022-2028 (IN $ MILLION)

FIGURE 25: EUROPE IMMUNOGLOBULIN MARKET, BY HOMECARE, 2022-2028 (IN $ MILLION)

FIGURE 26: EUROPE IMMUNOGLOBULIN MARKET, BY SALES CHANNEL, 2021 & 2028 (IN %)

FIGURE 27: EUROPE IMMUNOGLOBULIN MARKET, BY HOSPITAL PHARMACY, 2022-2028 (IN $ MILLION)

FIGURE 28: EUROPE IMMUNOGLOBULIN MARKET, BY SPECIALTY PHARMACY, 2022-2028 (IN $ MILLION)

FIGURE 29: EUROPE IMMUNOGLOBULIN MARKET, BY OTHER SALES CHANNELS, 2022-2028 (IN $ MILLION)

FIGURE 30: EUROPE IMMUNOGLOBULIN MARKET, COUNTRY OUTLOOK, 2021 & 2028 (IN %)

FIGURE 31: UNITED KINGDOM IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)

FIGURE 32: GERMANY IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)

FIGURE 33: FRANCE IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)

FIGURE 34: SPAIN IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)

FIGURE 35: ITALY IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)

FIGURE 36: REST OF EUROPE IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)

 

The growing incidence of immunodeficiency to fuel the demand for immunoglobulins in the European market

 

MARKET OUTLOOK

A study on the immunoglobulin market in Europe by Triton Market Research estimates that it would grow with a 6.81% CAGR over the forecasting years between 2022 and 2028. Italy, France, the United Kingdom, Germany, Spain, and Rest of Europe are studied in the market in this region.

With the prevalence of various immunodeficiency diseases, the growth of the biotechnology sector, and government initiatives for immunoglobulin and plasma donations in the region, the market’s growth has been significantly higher. Furthermore, the development of different vaccines across the region is also expected to drive the studied market’s growth. 

In France, the market growth is accelerated by the factors such as the growth in investments by market players and vaccine research & development activities by industry experts. For instance, in 2022, as part of its plan to invest $594 million in the country over the period of 5 years, Pfizer Inc announced it would add a production facility for the COVID-19 antiviral drug. Thus, such factors are expected to significantly impact the immunoglobulin market in the country during the forecasted period. 

In the United Kingdom, the presence of primary immunodeficiencies, along with increased susceptibility to infection & malignancy, and immune autoimmunity dysregulation, have resulted in the need for immunoglobulin products for treatment. Furthermore, the government in the region has initiated support for adopting immunoglobulin. For example, in 2021, the government permitted people to donate plasma for medicines. Thus, the stated factors are expected to promote the region’s immunoglobulin market growth. 

 

Get more insights into the Europe Immunoglobulin Market:

 

https://www.tritonmarketresearch.com/reports/europe-immunoglobulin-market

 

COMPETITIVE OUTLOOK

The dominant players in the immunoglobulin market include CSL Behring, Takeda Pharmaceutical Company Limited, Sanquin Plasma Products BV, Kamada Ltd, Sichuan Yuanda Shuyang Pharmaceutical Co Ltd, Pfizer Inc, Octapharma AG, and ADMA Biologics.

 

SEGMENTATION

1.     BIOTEST AG

2.     CHINA BIOLOGIC PRODUCTS INC

3.     GRIFOLS SA

4.     LFB GROUP

5.     CSL BEHRING

6.     KEDRION BIOPHARMA

7.     OCTAPHARMA AG

8.     TAKEDA PHARMACEUTICAL COMPANY LIMITED

9.     BIO PRODUCTS LABORATORY

10. SHANGHAI RAAS BLOOD PRODUCTS CO LTD

11. PFIZER INC

12. SANQUIN PLASMA PRODUCTS BV

13. ADMA BIOLOGICS

14. SICHUAN YUANDA SHUYANG PHARMACEUTICAL CO LTD

15. KAMADA LTD